Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 6, 2018

Primary Completion Date

December 24, 2018

Study Completion Date

August 27, 2021

Conditions

Solid Tumor

Interventions

DRUG

lenvatinib

once daily continuous dosing

Trial Locations (2)

Beijing Cancer Hospital, Beijing

Harbin Medical University Cancer Hospital, Harbin

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT03009292 - Pharmacokinetic Study of E7080/Lenvatinib in Chinese Subjects With Solid Tumor | Biotech Hunter | Biotech Hunter